Subscribe To

Price Alert Latest News Economic Calendar News

BVAXF / BioVaxys announces bioproduction of BVX-1021 for its pan-sarbecovirus vaccine program with Ohio State University

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) revealed that it has struck an agreement with Millipore-Sigma to manufacture a supply of GLP-grade BVX-1021, its newly developed vaccine for the strain of coronavirus that causes severe acute respiratory syndrome (SARS1), the respiratory illness responsible for the deadly 2002-2004 pandemic. The Vancouver-based clinical stage biotechnology company noted that there are no vaccines currently approved for SARS1. Read More

Demo Live Account See Partner Details

Content Topics

Biovaxys

Announces

Bioproduction

Bvx

1021

Pan

Sarbecovirus

Bvx 1021

Pan sarbecovirus

Vaccine

Program

University

Stock

BVAXF

Posted: Mar 17 2022, 09:57

Author Name: Proactive Investors

BVAXF News

By Proactive Investors
August 30, 2023

BioVaxys Technology extends collaboration with Ohio State University as new Covid variant raises concerns

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) told investors it has extended its research collaboration with The Ohio State University again as a

By Proactive Investors
June 15, 2023

BioVaxys Technology sells its medical software business, TAET Software

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) said it has sold its medical software business, TAET Software, to 10402588 BC Ltd, a private compan

By Proactive Investors
March 16, 2023

BioVaxys Technology acquires clinical study management company TAETSoftware; completes private placement

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) has announced that it has acquired TAETSoftware Corp (TAETCo), a Vancouver-based clinical studies m

By Proactive Investors
December 19, 2022

BioVaxys Technology finalizes US distribution deal with Procare Health Iberia for Papilocare Gel and Oral Immunocaps

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) told investors it has now finalized and executed the previously announced US distribution agreement

By Proactive Investors
December 1, 2022

BioVaxys Technology successfully tests production of ovarian cancer vaccine using a patient's ovarian tumor

BioVaxys Technology Corp has successfully completed a sterile and bacteria-free test-run production of its ovarian cancer vaccine BVX-0918, using a ca

By Proactive Investors
November 29, 2022

BioVaxys Technology closes first tranche of non-brokered private placement for total gross proceeds of $117,500

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) said it has closed the first tranche of a non-brokered private placement for total gross proceeds of

By Proactive Investors
November 16, 2022

BioVaxys says initial results from study into universal vaccine against Covid-19 virus family are promising

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) said interim results from its ongoing pre-clinical study shows its vaccine against a family of virus

By Proactive Investors
September 8, 2022

BioVaxys Technology adds experienced CFO Craig Loverock to its executive team

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) has named veteran financial executive Craig Loverock as its new CFO, the company announced. Lovero

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.